Francis Worden, MD

home / authors / francis-worden-md

Articles

Exploring Real-World Evidence Presented at ATA 2023

Lori J. Wirth, MD;Francis Worden, MD;Marcia S. Brose, MD, PhD;Daniel Bowles, MD;Hyunseok Kang, MD

April 26th 2024

Medical professionals discuss the recently published real-world evidence presented at the American Thyroid Association 2023 Conference.

Hyunseok Kang, MD, an expert on thyroid cancer

Determining Which DTC Patients May Benefit from Systemic Therapy

Lori J. Wirth, MD;Francis Worden, MD;Marcia S. Brose, MD, PhD;Daniel Bowles, MD;Hyunseok Kang, MD

April 26th 2024

Hyunseok Kang, MD, discusses the importance of balancing toxicities and other factors when initiating first-line treatments for patients with refractory differentiated thyroid cancer (DTC), while emphasizing the need to set clear goals and communicate potential adverse reactions before allowing patients to make informed decisions.

Diagnosing DTC: Clinical Workup and Molecular Testing

Lori J. Wirth, MD, Massachusetts General Hospital;Ezra Cohen, MD, FRCPSC, FASCO, UC San Diego;Francis Worden, MD;Marcia S. Brose, MD, PhD, University of Pennsylvania

April 17th 2023

Shared insight on best practices in diagnosing patients with differentiated thyroid cancer with a focus on histologic and molecular subtypes.

Overview on Differentiated Thyroid Cancer (DTC)

Lori J. Wirth, MD, Massachusetts General Hospital;Ezra Cohen, MD, FRCPSC, FASCO, UC San Diego;Francis Worden, MD;Marcia Brose, MD, PhD, University of Pennsylvania

April 17th 2023

Opening discussion on the advent of differentiated thyroid cancer (DTC) and management, moderator Lori J. Wirth, MD, provides and overview of prevalence, subtypes, and prognosis.